Search
Anastrozole
go.drugbank.com/drugs/DB01217ApprovedInvestigationalAnastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to e...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: ANASTROZOLO DOC GENERICI, ANASTROZOLO MYLAN GENERICSChlorprothixene
go.drugbank.com/drugs/DB01239ApprovedInvestigationalWithdrawnChlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.
Categories: P-glycoprotein inhibitorsGemfibrozil
go.drugbank.com/drugs/DB01241ApprovedInvestigationalGemfibrozil is a fibric acid agent, similar to clofibrate, used to treat Type IIb, IV, and V hyperlipidemias. Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet,...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsProducts: GEMFIBROZIL DOC GENERICIArformoterol
go.drugbank.com/drugs/DB01274ApprovedArformoterol is a bronchodilator. It works by relaxing muscles in the airways to improve breathing. Arformoterol inhalation is used to prevent bronchoconstriction in people with chronic obstructive pulmonary disease, including chronic br...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesGlisoxepide
go.drugbank.com/drugs/DB01289InvestigationalGlisoxepide is one of the sulphonamide-derived oral antidiabetic drugs. It inhibits the uptake of bile acids into isolated rat hepatocytes. However it inhibits taurocholate uptake only in the absence of sodium ions. Glisoxepide uptake co...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesSulfacytine
go.drugbank.com/drugs/DB01298ApprovedSulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle.
Tasosartan
go.drugbank.com/drugs/DB01349ExperimentalTasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. It is used to treat patients with essential hypertension.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAprobarbital
go.drugbank.com/drugs/DB01352ExperimentalIllicitAprobarbital is a barbiturate derivative synthesized in the 1920s by Ernst Preiswerk. It was determined that the substance was capable of demonstrating sedative, hypnotic, and anticonvulsant effects. A primary treatment indicated for the...
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersTemafloxacin
go.drugbank.com/drugs/DB01405ApprovedWithdrawnTemafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reacti...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsPranlukast
go.drugbank.com/drugs/DB01411InvestigationalPranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Inhibitors